BiotechTube

Esomeprazole Magnesium

ApprovedWithdrawn
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Dyspepsia

Conditions

Dyspepsia

Trial Timeline

Dec 1, 2006 → Dec 1, 2006

NCT ID
NCT00443963

About Esomeprazole Magnesium

Esomeprazole Magnesium is a approved stage product being developed by AstraZeneca for Dyspepsia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00443963. Target conditions include Dyspepsia.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (3)

NCT IDPhaseStatus
NCT00443963ApprovedWithdrawn
NCT00687245Phase 1Completed
NCT00637559ApprovedCompleted

Competing Products

20 competing products in Dyspepsia

See all competitors
ProductCompanyStageHype Score
YH12852 0.1 mg + YH12852 0.25 mg + YH12852 0.5 mg + PlaceboYuhanPhase 2
52
YM443 + Placebo + MoxifloxacinAstellas PharmaPhase 1
33
YM443Astellas PharmaPhase 3
77
Cinitapride + domperidoneEisaiPhase 3
77
Rabeprazole + Rabeprazole + Rabeprazole + PlaceboEisaiPhase 2
52
Z-338Zeria PharmaceuticalPhase 3
76
Imonogas + EspumisanJohnson & JohnsonPhase 3
77
esomeprazoleAstraZenecaApproved
85
TegaserodNovartisPhase 3
77
TegaserodNovartisPhase 3
77
TegaserodNovartisPhase 3
77
Tegaserod and PlaceboNovartisApproved
85
TegaserodNovartisPhase 3
77
TegaserodNovartisPhase 3
77
Gabapentin + PlaceboPfizerPhase 3
76
Z-338Zeria PharmaceuticalPhase 2
51
Z-338Zeria PharmaceuticalPhase 2
51
Z-338Zeria PharmaceuticalPhase 2
51
Z-338 + PlaceboZeria PharmaceuticalPhase 3
76
Acotiamide hydrochloride hydrate + PlaceboZeria PharmaceuticalPhase 3
76

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85